

The Advancements in Diagnosis and Treatment of Rheumatic Heart Disease

Sidarth Krishna*

Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India

DESCRIPTION

Rheumatic Heart Disease (RHD) is a serious and potentially life-threatening condition that affects millions of people worldwide. It is caused by a bacterial infection called strep throat, which can lead to an inflammatory response in the heart and damage the heart valves. RHD is most common in developing countries, where access to healthcare and preventive measures such as antibiotics is limited. However, advancements in diagnosis and treatment have improved the outlook for people with RHD. One major advancement in the diagnosis of RHD is the use of echocardiography, a non-invasive imaging technique that uses sound waves to create images of the heart. Echocardiography is more accurate than traditional methods such as auscultation, which involves listening to the heart with a stethoscope [1].

Echocardiography can detect even mild valve abnormalities and can monitor the progression of the disease over time. This early detection allows for timely intervention and management of the disease, which can improve outcomes for patients. Another significant advancement in RHD treatment is the use of penicillin prophylaxis, which involves the regular administration of antibiotics to prevent the recurrence of strep throat infections. This approach has been shown to be highly effective in preventing the development and progression of RHD. In addition, surgical interventions such as valve replacement or repair can also improve outcomes for patients with severe RHD

Despite these advancements, RHD remains a significant global health concern. It is estimated that over 30 million people worldwide are affected by RHD, and over 300,000 people die from the disease each year. RHD disproportionately affects children and young adults, who may develop lifelong complications from the disease [2]. There is a pressing need for continued research and innovation to improve the diagnosis and treatment of RHD. One promising area of research is the development of a RHD vaccine. A vaccine would provide long-term protection against the strep bacteria that cause RHD and could significantly reduce the global burden of the disease. Several vaccines are currently in development, and early studies

have shown promising results [3]. However, more research is needed to determine the safety and efficacy of these vaccines in large-scale clinical trials. Another area of research is the use of biomarkers to predict the development and progression of RHD. Biomarkers are measurable substances in the body that can indicate the presence of disease. By identifying specific biomarkers associated with RHD, clinicians could potentially diagnose the disease earlier and monitor its progression more accurately. This could lead to earlier intervention and improved outcomes for patients [4,5].

CONCLUSION

In conclusion, the advancement of RHD diagnosis and treatment has improved the outlook for people with this serious disease. Echocardiography, penicillin prophylaxis, and surgical interventions have all played a significant role in improving outcomes for patients with RHD. However, there is still much work to be done to reduce the global burden of RHD. Continued research and innovation, including the development of a RHD vaccine and the use of biomarkers, hold promise for further improving the diagnosis and treatment of RHD. Ultimately, these advancements have the potential to save countless lives and improve the health and wellbeing of people around the world.

REFERENCES

1. Eisenberg MJ. Rheumatic heart disease in the developing world: prevalence, prevention, and control. *Eur Heart J.* 1993;14:122-128.
2. Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, Jani D. Prevalence of rheumatic heart disease detected by echocardiographic screening. *N Engl J Med.* 2007;357: 470-476.
3. Padmavati S. Rheumatic heart disease: prevalence and preventive measures in the Indian subcontinent. *Heart.* 2001;86:127.
4. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. *Lancet Infect Dis.* 2005;5:685-694.
5. Damasceno A, Cotter G, Dzudie A, Sliwa K, Mayosi BM. Heart failure in sub-Saharan Africa: time for action. *J Am Coll Cardiol.* 2007;50:1688-1693.

Correspondence to: Sidarth Krishna, Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India, E-mail: Krishnas34@gmail.com

Received: 28-Feb-2023, Manuscript No. JCEC-23-22694; **Editor assigned:** 03-Mar-2023, Pre QC No. JCEC-23-22694 (PQ); **Reviewed:** 21-Mar-2023, QC No. JCEC-23-22694; **Revised:** 28-Mar-2023, Manuscript No. JCEC-23-22694 (R); **Published:** 05-Apr-2023, DOI: 10.35248/2155-9880.23.14.778

Citation: Krishna S (2023) The Advancements in Diagnosis and Treatment of Rheumatic Heart Disease. *J Clin Exp Cardiol.* 14:778.

Copyright: ©2023 Krishna S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.